2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
Gambardella V, Accordino M, Bedard P, Cervantes A, Hamilton E, Italiano A, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Fernandez-Saranillo A, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman J, Juric D, Jhaveri K. Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). ESMO Open 2025, 10: 105303. PMID: 40513140, PMCID: PMC12205636, DOI: 10.1016/j.esmoop.2025.105303.Peer-Reviewed Original ResearchHER2-negative advanced breast cancerAdvanced breast cancerAdverse eventsCombination therapyPIK3CA-mutationsBreast cancerHormone receptor (HR)-positiveDiscontinued study treatmentBreast cancer therapyLong-term toleranceDose reductions/interruptionsAny-gradeData cutoffDose modificationTolerability profileHR-positiveProgressive diseaseStudy treatmentMetformin treatmentCancer therapyNo treatmentPatientsRisk factorsTherapyHyperglycemia
2024
Single-cell transcriptomics of CD8 T cells in autoimmune diabetes after anti-CD3 monoclonal antibody treatment
Wu Y, Spurrell M, Deng S, Herold K. Single-cell transcriptomics of CD8 T cells in autoimmune diabetes after anti-CD3 monoclonal antibody treatment. The Journal Of Immunology 2024, 212: 0998_4625-0998_4625. DOI: 10.4049/jimmunol.212.supp.0998.4625.Peer-Reviewed Original ResearchPancreas-draining lymph nodesIslet-infiltrating CD8 T cellsCD8 T cellsPre-diabetic NODAnti-CD3 mAbDiverse TCR repertoireT cellsNOD miceTCR repertoireTCF-1Pre-diabetic NOD miceImmune mediated destructionDiabetic NOD miceMonoclonal antibody treatmentLong-term toleranceExpression of EomesExpression of TCF-1Expression of TOXFragments of mAbsDelay type 1 diabetesType 1 diabetesAnti-CD3Autoimmune diabetesAntibody treatmentLymph nodes
2018
B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells
Yu W, Chen L, Guo S, Luo L, Chen L. B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells. OncoImmunology 2018, 7: e1504156. PMID: 30574431, PMCID: PMC6298416, DOI: 10.1080/2162402x.2018.1504156.Peer-Reviewed Original ResearchAllogeneic T cellsT cellsB7-H1Systemic inflammationPD-1B7-H1 monoclonal antibodyB7-H1/PDAllogeneic T-cell responsesB7-H1 mAbProgression of GVHDT cell responsesCo-inhibitory pathwaysT-cell lysisLong-term toleranceHost cell destructionNormal hematopoietic cellsDisseminated inflammationHost diseaseLeukemia responseAccelerated progressionMouse modelCell destructionInflammationMonoclonal antibodiesTypes of cells
2007
Vascularized composite islet-kidney transplantation in a miniature swine model
Vallabhajosyula P, Griesemer A, Yamada K, Sachs DH. Vascularized composite islet-kidney transplantation in a miniature swine model. Cell Biochemistry And Biophysics 2007, 48: 201-207. PMID: 17709890, DOI: 10.1007/s12013-007-0027-4.Peer-Reviewed Original ResearchConceptsThymic tissueIslet equivalentsEnd-stage diabetic nephropathyType I diabetic patientsAllogeneic thymic tissueRecipient body weightLong-term toleranceLong-term survivalMiniature swine modelKidney allograftsMHC barriersDiabetic nephropathyAllogeneic isletsAllogeneic transplantationDiabetic hyperglycemiaDiabetic patientsThymic componentsTreatment regimensPortal veinRenal capsuleOrgan transplantsAutologous isletsMiniature swineTransplantationBody weight
2001
LONG-TERM ISLET ALLOGRAFT FUNCTION IN THE ABSENCE OF CHRONIC IMMUNOSUPPRESSION: A CASE REPORT OF A NONHUMAN PRIMATE PREVIOUSLY MADE TOLERANT TO A RENAL ALLOGRAFT FROM THE SAME DONOR1
Kawai T, Sogawa H, Koulmanda M, Smith R, O’Neil J, Wee S, Boskovic S, Sykes M, Colvin R, Sachs D, Auchincloss H, Cosimi A, Ko D. LONG-TERM ISLET ALLOGRAFT FUNCTION IN THE ABSENCE OF CHRONIC IMMUNOSUPPRESSION: A CASE REPORT OF A NONHUMAN PRIMATE PREVIOUSLY MADE TOLERANT TO A RENAL ALLOGRAFT FROM THE SAME DONOR1. Transplantation 2001, 72: 351-354. PMID: 11477369, DOI: 10.1097/00007890-200107270-00036.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAnimalsAntilymphocyte SerumBlood GlucoseBone Marrow TransplantationCell SeparationC-PeptideCyclosporineDiabetes Mellitus, ExperimentalGraft SurvivalHistocompatibility TestingImmunosuppression TherapyInsulinIslets of LangerhansMacaca fascicularisMajor Histocompatibility ComplexMaleSplenectomyTransplantation, HomologousWhole-Body IrradiationConceptsDonor bone marrow transplantationEvidence of rejectionLong-term toleranceLong-term islet allograft functionHistological evidenceIslet transplantationHistologic evidence of rejectionWeeks of cyclosporineSolid organ allograftsTotal body irradiationBone marrow transplantationStreptozocin-induced diabetesIslet allograft functionNonmyeloablative conditioningThymic irradiationChronic immunosuppressionRecurrent diabetesAllograft functionBody irradiationMarrow transplantationNative nephrectomyKidney allograftsOrgan allograftsRenal allograftsKidney rejection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply